Skip to main content
. 2021 Aug 12;10(16):3535. doi: 10.3390/jcm10163535

Table 1.

Characteristics of the included articles.

Author (Publication Year) Study Design Study Location Cohort of Surveillance No. of Patients
(%
Cirrhosis)
Age, Years * Most Common Etiology No. of Patients with HCC US Machine Sonographer Experience Test for Surveillance Interval of Test Reference Standard Follow-Up Period, Months *
Kim YY (2019) Retrospective South Korea Patients with hepatic observation 155 (N.A.) 59.4 ±
8.9 *
Hepatitis B 155 NA 1–4 years US plus AFP 6 months Pathology, CT or
MRI
NA
Millet JD (2019) Retrospective U.S. Total cohort ** 2050 (51.4) 57.7, mean Hepatitis B 29 Multiple 19.3 ± 12.3 * US plus AFP 6 months Pathology, CT or
MRI
21.7 ± 2.7 *
Pinero F (2019) Retrospective Argentina Patients with hepatic observation 345
(100)
62 ± 8.8 *
61 ± 9.6 *
Hepatitis C 345 NA NA US plus AFP 6 months Pathology, CT or
MRI
NA
Son JH (2019) Retrospective South Korea Total cohort ** 407
(100)
56,
median (28–76)
Hepatitis B 28 Single >14 years US alone 6 months Pathology, CT or
MRI
18, median
Samoylova ML (2018) Retrospective U.S. Patients with hepatic observation 352 (NA) 60,
median (56–65)
Hepatitis C 352 NA NA US plus AFP NA CT or
MRI
NA
Simmons O (2017) Retrospective U.S. Total cohort ** 941
(100)
56.5 ±
9.9 *
Hepatitis C NA Multiple NA US plus AFP 6 months NA NA

Articles are listed according to the year of publication and alphabetical order of the names of the first authors within the same year of publication. * Data are presented as the means ± standard deviations. ** Total cohort includes patients without hepatic observations as well as those with hepatic observations. HCC, hepatocellular carcinoma; No, number; US, ultrasound; AFP, alpha-fetoprotein; CT, computed tomography; MRI, magnetic resonance imaging; NA, not available.